Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Coronary Atherosclerotic Heart Disease (Epicardial Adipose Tissue Study)
ChiCTR2100049957Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of evolocumab in coronary arteriosclerosis, hyperlipidemia and dyslipidemia, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Volume of epicardial adipose tissue. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
coronary arteriosclerosishyperlipidemiadyslipidemia
Beyond the preview
Go deeper on ChiCTR2100049957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049957.